학술논문
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Document Type
article
Author
Gitelman, Stephen E; Bundy, Brian N; Ferrannini, Ele; Lim, Noha; Blanchfield, J Lori; DiMeglio, Linda A; Felner, Eric I; Gaglia, Jason L; Gottlieb, Peter A; Long, S Alice; Mari, Andrea; Mirmira, Raghavendra G; Raskin, Philip; Sanda, Srinath; Tsalikian, Eva; Wentworth, John M; Willi, Steven M; Krischer, Jeffrey P; Bluestone, Jeffrey A; Group, Gleevec Trial Study; Barr, Mayalin; Buchanan, Jeanne; Cabbage, Joanne; Coleman, Peter; De La Vega, Monica; Evans-Molina, Carmella; Ferrara, Christine; Healy, Felicity; Higgins, Laurie; Hildinger, Megan; Jenkins, Margaret; Bryant, Nora Kayton; Kinderman, Amanda; Koshy, Nisha; Kost, Brianne; Krishfield, Suzanne; Kucheruk, Olena; Lindsley, Karen; Mantravadi, Manasa; Mesfin, Shelley; Michels, Aaron; Migre, Mary Ellen; Minnock, Pantea; Mohammed-Nur, Elham; Nelson, Jennifer; Nursing, Ashvin; O'Donnell, Ryan; Olivos, Diana; Parker, Melissa; Redl, Leanne; Reed, Nicole; Resnick, Brittany; Sayre, Peter; Serti, Elisavet; Sims, Emily; Smith, Karen; Soppe, Carol; Stuart, Fiona; Szubowicz, Sarah; Tansey, Michel; Terrell, Jennifer; Tersey, Sarah; Torok, Christine; Watson, Kelly; Wesch, Rebecca; Willi, Steven; Woerner, Stephanie
Source
The Lancet Diabetes & Endocrinology. 9(8)
Subject
Language
Abstract
BackgroundType 1 diabetes results from autoimmune-mediated destruction of β cells. The tyrosine kinase inhibitor imatinib might affect relevant immunological and metabolic pathways, and preclinical studies show that it reverses and prevents diabetes. Our aim was to evaluate the safety and efficacy of imatinib in preserving β-cell function in patients with recent-onset type 1 diabetes.MethodsWe did a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Patients with recent-onset type 1 diabetes (